×
About 2,728 results

ALLMedicine™ Retinal Vein Occlusion Center

Research & Reviews  930 results

Characteristics and risk factors of retinal vasculopathy in antiphospholipid syndrome.
https://doi.org/10.1177/09612033211069762
Lupus Xie Z, Li H et. al.

Jan 20th, 2022 - Retinal vasculopathy including retinal artery occlusion (RAO) or retinal vein occlusion (RVO) was recently found to occur more frequently in antiphospholipid syndrome (APS) patients than non-APS patients. This study aims to investigate the clinica...

Vitamin B12 levels in patients with retinal vein occlusion and their relation with clin...
https://doi.org/10.1007/s11739-021-02905-7 10.1055/a-1473-5897
Internal and Emergency Medicine; Paciullo F, Menduno PS et. al.

Jan 15th, 2022 - Retinal vein occlusion (RVO) is the second most common retinal vascular disorder, after diabetic retinopathy. Most patients suffering RVO develop some degree of visual loss consequent to retinal complications such as edema and microhemorrhages. Ev...

Central Retinal Vein Occlusion Following BNT162b2 (Pfizer-BioNTech) COVID-19 Messenger ...
https://doi.org/10.1097/ICB.0000000000001214
Retinal Cases & Brief Reports; Shah PP, Gelnick S et. al.

Jan 14th, 2022 - Coronavirus disease 2019 (COVID-19) has had a wide-ranging public health impact, contributing to at least 5 million deaths globally at the time of this report. Although thromboembolic events following COVID-19 vaccination have been an ongoing conc...

Central Retinal Vein Occlusion-What Is the Potential Importance of Persistent and Recur...
https://doi.org/10.1001/jamaophthalmol.2021.5620
JAMA Ophthalmology; Popovic MM, Kertes PJ

Jan 7th, 2022 - Central Retinal Vein Occlusion-What Is the Potential Importance of Persistent and Recurrent Macular Edema?|2022|Popovic MM,Kertes PJ,|

Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal...
https://doi.org/10.1001/jamaophthalmol.2021.5619
JAMA Ophthalmology; Gurudas S, Patrao N et. al.

Jan 7th, 2022 - It is unclear how visual outcomes vary between patterns of macular edema (ME) resolution in eyes with central retinal vein occlusion (CRVO). To assess best-corrected visual acuity (BCVA) outcomes at 100 weeks based on macular fluid resolution patt...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  66 results

Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
https://clinicaltrials.gov/ct2/show/NCT02006147

Dec 23rd, 2021 - An open-label, sequential dose escalation part to determine the DLT of TLC399 (ProDex) in patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). The safety results should be evalu...

Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation
https://clinicaltrials.gov/ct2/show/NCT05138029

Dec 8th, 2021 - Test method: Include suitable cases of diabetic retinopathy and macular edema Inclusion criteria: a. PDR patients with severe vitreous hemorrhage who cannot collect oct images and require vitrectomy b. Type 2 diabetes, aged 18~80 years old c. Good...

An Innovative Chinese Herbal Formula for Macular Edema
https://clinicaltrials.gov/ct2/show/NCT05122702

Nov 17th, 2021 - Macular edema (ME) is characterized by hyperpermeability of retinal vessels and/or decreased efflux of fluid across the retinal pigment epithelium, and the condition can be induced by outer/inner blood-retinal barrier dysfunction (BRB). It is most...

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
https://clinicaltrials.gov/ct2/show/NCT01875770

Oct 12th, 2021 - People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long te...

Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema and CRVO
https://clinicaltrials.gov/ct2/show/NCT04690608

Oct 5th, 2021 - Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus and 60 eyes with central retinal vein occlusion will be included. The study will be conduc...

see more →

News  88 results

FDA Approves First Biosimilar for Ranibizumab Intravitreal Injections, nAMD
https://www.medscape.com/viewarticle/959087

Sep 20th, 2021 - The US Food and Drug Administration (FDA) has approved the first biosimilar for ophthalmology, Byooviz (ranibizumab-nuna), which will be indicated for neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein ...

Anti-VEGF Injections Preserved Vision in Severe Diabetic Retinopathy
https://www.medpagetoday.com/ophthalmology/generalophthalmology/93910

Aug 5th, 2021 - Intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor reduced disease severity and vision-threatening complications in patients with severe nonproliferative diabetic retinopathy (NPDR), the phase III PANORAMA trial found...

COVID Delay of Treatment of Neovascular Age-Related Macular Degeneration Less Harmful Than Expected
https://www.medscape.com/viewarticle/950709

May 6th, 2021 - Many people with neovascular age-related macular degeneration (nAMD) lost less vision than expected during treatment delays imposed by COVID-19, researchers say. The finding suggests that physicians may be overtreating these patients, said James T...

Binimetinib Shows Rare PFS Benefit in NRAS-Mutant Melanoma
https://www.onclive.com/view/binimetinib-shows-rare-pfs-benefit-in-nrasmutant-melanoma

Dec 20th, 2020 - Reinhard Dummer, MD The MEK inhibitor binimetinib reduced the risk of progression or death by 38% compared with dacarbazine in patients with NRAS-mutant metastatic melanoma, according to findings from the phase III NEMO study presented at the 201...

High Response Rate in Histiocytic Disease With MEK Inhibition
https://www.onclive.com/view/high-response-rate-in-histiocytic-disease-with-mek-inhibition

Dec 20th, 2020 - Eli Diamond, MD The MEK inhibitor cobimetinib (Cotellic) led to objective responses in 14 of 16 patients with BRAF-mutated and wild-type histiocytic disorders, according to results of a phase II trial presented at the 2017 ASH Annual Meeting. Th...

see more →

Patient Education  2 results see all →